BioVaxys Technology Corp., a clinical-stage biopharmaceutical company specializing in durable single-dose vaccines for cancer and infectious diseases, will participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9-10, 2026. CEO James Passin will deliver a presentation and hold one-on-one investor meetings, highlighting the company's innovative DPX™ vaccine platform and ongoing clinical trials in oncology and infectious diseases. This event offers BioVaxys a platform to engage with investors and industry leaders, potentially advancing its development and funding opportunities.
Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...
EVI Industries reported Q4 revenue of $121.87 million, surpassing analyst expectations of $117.1 million, and achieved a record fiscal year revenue of $446.6 million, marking a 15% increase year-over-year. The company met earnings per share forecasts...
Lakeland Industries continues to face profitability challenges with a projected negative EPS of -$0.06 and recent unprofitability. However, the company secured important contracts with the Hong Kong Government Flying Service and Airports of Thailand,...
Apple has acquired Sonera, a company specializing in non-invasive neural signal sensors that can measure brain activity for applications like muscle monitoring and thought control of devices. This technology could enable thought-controlled Apple prod...
RUM Group's stock surged 33% in the past month, driven by its expansion into AI infrastructure through the acquisition of Northern Data and strong Q2 revenue growth of 61% year-over-year to $40.4 million. The company now operates both a video platfor...
